Lets try and extend this discussion a bit Redbar from a couple of points you have made.
The FDA panel told RAP it wanted to see a US double blind clinical trial that produced statistically significant results.
For the benefit of the forum would you like to offer an opinion about:
Have a crack if it takes your fancy and we can see where the discussion heads.
- Why did the FDA panel want to see statistically significant results?
- What statistically significant results (if any) were produced from the US trial?
Ann: ResApp Submits De Novo Application to the FDA, page-78
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #